Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions

Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact... Patient reported outcomes (PROs) are commonly integrated into clinical trials for new cancer therapies or treatment modalities; however, beyond a cursory review during the registration process for a new drug, these important measures of patient satisfaction and cost-effectiveness are often under-used in daily practice. We cite literature under-scoring the value of PROs not only in clinical trials, but in practical decision making and how such metrics can help guide the oncologist and the patient in choosing the best and most cost-effective therapy for their cancer. This is especially critical with the advent of new immunotherapies that are proving to be therapeutically beneficial for many patients, but not all, and at substantial cost in terms of toxicities and financial impact. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions

Mott, Frank
Oncology and Therapy , Volume 5 (1) – Jan 5, 2017
Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/patient-reported-outcomes-pros-as-part-of-value-based-care-can-shape-CL0t2GJd3y
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0038-7
Publisher site
See Article on Publisher Site

Abstract

Patient reported outcomes (PROs) are commonly integrated into clinical trials for new cancer therapies or treatment modalities; however, beyond a cursory review during the registration process for a new drug, these important measures of patient satisfaction and cost-effectiveness are often under-used in daily practice. We cite literature under-scoring the value of PROs not only in clinical trials, but in practical decision making and how such metrics can help guide the oncologist and the patient in choosing the best and most cost-effective therapy for their cancer. This is especially critical with the advent of new immunotherapies that are proving to be therapeutically beneficial for many patients, but not all, and at substantial cost in terms of toxicities and financial impact.

Journal

Oncology and Therapy – Springer Journals

Published: Jan 5, 2017

References

  • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
    Seto, T; Kiura, K; Nishio, M
  • Nivolumab versus docetaxel in advanced squamous cell non-small cell lung cancer
    Brahmer, J; Reckamp, KL; Baas, P
  • Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer
    Borghaei, H; Pax-Ares, L; Horn, L
  • Pembrolizumab for the treatment of non-small-cell lung cancer
    Garon, EB; Rizvi, NA; Hui, R
  • Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modelling approaches to estimate and extrapolate survival outcomes
    Goeree, R; Villeneuve, J; Goeree, J
  • Patient-reported outcome performance measures in Oncology
    Basch, E; Snyder, C; McNiff, K
  • Patient-reported outcomes labeling for products approved by the office of hematology and oncology products of the US Food and Drug Administration (2010–2014)
    Gnanasakthy, A; DeMuro, C; Clark, M
  • Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week
    Shi, Q; Wang, XS; Mendoza, TR
  • Circulating tumor DNA as a liquid biopsy for cancer
    Heitzer, E; Ulz, P; Geig, J
  • Liquid biopsies: genotyping circulating tumor DNA
    Diaz, L; Bardelli, A
  • Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory
    Cleeland, CS; Mendoza, TR; Wang, XS